4Wei H,Hai W,Wanqing L.Clinical study on liposomal amphotericin B (Ambisome)in deep fungal infections in China[J].Mycoses,2003,46(1～2):24～28. 被引量：1
5Cagnoni PJ. Liposomal amphotericin B versus conventional am～photericinB in the empirical treatment of persistently febrile neutropenic patients[J].J Antimicrob Chemother,2002,49(SuppISI):81～86. 被引量：1
6Garber G. An overview of fungal infections[J]. Drugs,2001,61 (Suppl 1):1-12. 被引量：1
7Francis C, Szoka, JR. , Effect of Lipid Composition and Liposome size on toxicity and in vitro fungicidal activity of liposomeintercalated amphotericin B [J]. Antimicrobial Agents and Chemotherapy,May. 1987,421-429. 被引量：1
8Gulati M, Baiad S, Singh S, et al. Development of liposomal amphotericin B formulation[J]. Microencapsul, 1998, 15 (2): 137-151. 被引量：1
9ELS WM, Van Etten, Marian T. et al. Amphotericin B Liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and ffficacy in systemic candidiasis in leukopenic mice[J]. Antimicrobial Agents and Chemotherapy, Sept, 1995,1954-1958. 被引量：1
10Proffitt~,Richard T, Adler-Moore,et al. Amphotericin B liposome preparation. US: 6,770,290[P]. August 3, 2004. 被引量：1
9Pfaller M A, Diekema D J, Jones R N, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infection:SENTRY Antimierobial Surveillance Program, 1997 to 2000 [J]. J Chin Mierobiol, 2002, 40: 852. 被引量：1
10Tawara S, Ikeda F, Maki K, et al. In vitro activi ties of a new lipopeptide antifungal agent mieafungin against a variety of clinically important fungi[J ]. Antimicrob Agents Chemother, 2000, 44(1): 57. 被引量：1
